We are live on !
Find out more
Affinity Asset Advisors Portfolio holdings
AUM
$2.21B
Turnover
29.69%
1-Year Est. Return
431.26%
This Fund
S&P 500
This Quarter Est. Return
+29.83%
1 Year Est. Return
+431.26%
3 Year Est. Return
+1,487.3%
5 Year Est. Return
+3,318.95%
10 Year Est. Return
–
AUM
$2.21B
AUM Growth
+$276M
(+14%)
Cap. Flow
-$34.2M
Cap. Flow % of AUM
Cap. Flow %
-1.55%
Top 10 Holdings %
Top 10 Hldgs %
39.41%
Holding
128
New
23
Increased
32
Reduced
32
Closed
15
Avg Time Held
Equity + Options
1
year
Top 10 Avg Time Held
Equity + Options
0.8
years
Top 20 Avg Time Held
Equity + Options
0.7
years
Avg Time Held Equity only
1.1
years
Top 10 Avg Time Held Equity only
0.8
years
Top 20 Avg Time Held Equity only
0.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
First Tracks Biotherapeutics
TRAX
|
+$38M |
| 2 |
Roivant Sciences
ROIV
|
+$28.1M |
| 3 |
Avalo Therapeutics
AVTX
|
+$24.6M |
| 4 |
Revolution Medicines
RVMD
|
+$21.9M |
| 5 |
Insmed
INSM
|
+$20.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$55.6M |
| 2 |
Arcellx
ACLX
|
+$41.7M |
| 3 |
Teva Pharmaceutical Industries Limited
TEVA
|
+$34.2M |
| 4 |
Terns Pharmaceuticals
TERN
|
+$29.7M |
| 5 |
Apogee Therapeutics
APGE
|
+$26.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 89.73% |
| 2 | Miscellaneous | 9.21% |
| 3 | Financials | 1.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
101
OnKure Therapeutics
OKUR
$102M
| $1.1M | 0.05% |
240,963
| – | – |
2026 Q1
1 quarter
|
|
102
enGene Therapeutics
ENGN
$105M
| $1.04M | 0.05% |
600,000
-10,370
| -2% | -$42.3K |
2025 Q2
4 quarters
|
|
103
X4 Pharmaceuticals
XFOR
$321M
| $677K | 0.03% |
145,000
| – | – |
2025 Q4
2 quarters
|
|
104
Boundless Bio
BOLD
$54.5M
| $625K | 0.03% |
+250,000
| New | +$385K |
2026 Q2
0 quarters
|
|
105
LENZ Therapeutics
LENZ
$99.3M
| $568K | 0.03% |
100,000
| – | – |
2026 Q1
1 quarter
|
|
106
Q32 Bio
QTTB
$258M
| $354K | 0.02% |
27,777
| – | – |
2024 Q1
9 quarters
|
|
107
Orchestra BioMed
OBIO
$336M
| $144K | 0.01% |
33,400
-369,150
| -92% | -$1.51M |
2025 Q3
3 quarters
|
|
108
NextCure
NXTC
$22.8M
| $67.1K | ﹤0.01% |
41,960
-199,866
| -83% | -$1.48M |
2024 Q1
9 quarters
|
|
109
Adagio Medical Holdings
ADGM
$2.82M
| $52.1K | ﹤0.01% |
80,000
| – | – |
2024 Q3
7 quarters
|
|
110
DELISTED
Rocket Pharmaceuticals Warrant
RCKTW
| $278 | ﹤0.01% |
75,000
| – | – |
2023 Q1
13 quarters
|
|
|
111
DELISTED
Arcellx
ACLX
| – | – |
-362,764
| Closed | -$41.7M | – |
|
112
BridgeBio Pharma
BBIO
$13.4B
| – | – |
-150,000
| Closed | -$11.1M | – |
|
113
CALL
Bristol-Myers Squibb
BMY
$126B
| – | – |
-300,000
| Closed | -$18.2M | – |
|
114
CALL
Celcuity
CELC
$3.19B
| – | – |
-30,000
| Closed | -$3.42M | – |
|
115
CALL
CG Oncology
CGON
$5.47B
| – | – |
-60,000
| Closed | -$4.06M | – |
|
|
CNTA
116
DELISTED
Centessa Pharmaceuticals
CNTA
| – | – |
-1,400,000
| Closed | -$55.6M | – |
|
117
Corcept Therapeutics
CORT
$9.28B
| – | – |
-50,000
| Closed | -$2.02M | – |
|
118
CALL
Dianthus Therapeutics
DNTH
$4.29B
| – | – |
-50,000
| Closed | -$4.2M | – |
|
119
PUT
ImmunityBio
IBRX
$8.71B
| – | – |
-1,250,000
| Closed | -$9.6M | – |
|
120
DELISTED
Kezar Life Sciences
KZR
| – | – |
-229,076
| Closed | -$1.7M | – |
|
121
CALL
Novo Nordisk
NVO
$172B
| – | – |
-175,000
| Closed | -$6.43M | – |
|
|
122
PUT
Revolution Medicines
RVMD
$40.1B
| – | – |
-100,000
| Closed | -$9.7M | – |
|
123
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$810B
| – | – |
-200,000
| Closed | -$130M | – |
|
|
124
DELISTED
Terns Pharmaceuticals
TERN
| – | – |
-562,631
| Closed | -$29.7M | – |
|
125
Wave Life Sciences
WVE
$627M
| – | – |
-1,401,727
| Closed | -$10.2M | – |
|
Similar funds
Affinity Asset Advisors's Q2 2026 Portfolio in Review
As of Q2 2026, Affinity Asset Advisors held 128 positions worth $2.21B, up 14% from $1.94B the previous quarter. Its ten largest holdings account for 39% of the portfolio.
Affinity Asset Advisors's Q2 2026 filing shows 23 new, 32 increased, 32 reduced and 15 closed positions. Its largest new stake was First Tracks Biotherapeutics: 2,032,012 shares worth $40.9M. The largest sale was Centessa Pharmaceuticals, an estimated $55.6M.
By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 86% a quarter earlier, followed by Miscellaneous and Financials.
- Affinity Asset Advisors's largest Q2 2026 buy was First Tracks Biotherapeutics: 2,032,012 shares worth $40.9M.
- Affinity Asset Advisors added most to Roivant Sciences in Q2 2026, an estimated $28.1M increase.
- Affinity Asset Advisors's biggest Q2 2026 reduction was Teva Pharmaceutical Industries Limited, cutting an estimated $34.2M.
- Affinity Asset Advisors fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $55.6M.
- Affinity Asset Advisors's ten largest holdings make up 39% of its $2.21B portfolio in Q2 2026.
- Affinity Asset Advisors opened 23 new positions and closed 15 in Q2 2026.
- Affinity Asset Advisors's portfolio value rose 14% quarter-over-quarter to $2.21B.
Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.